177 results on '"Raggi A"'
Search Results
2. MP77-11 NOMOGRAM PREDICTING OPTIMAL CANDIDATES FOR BLADDER-SPARING STRATEGIES AFTER NEOADJUVANT IMMUNOTHERAPY
3. MP14-10 IDENTIFYING THE OPTIMAL CANDIDATE FOR CONCOMITANT ANDROGEN-DEPRIVATION THERAPY AMONG PATIENTS RECEIVING METASTASIS-DIRECTED THERAPY FOR POSITIVE PSMA PET AND PRIMARY OR SECONDARY BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
4. MP14-13 EXPLORING THE INTERACTION BETWEEN THE USE OF METASTASIS DIRECTED THERAPY IN PATIENTS WITH POSITIVE PSMA PET AND PATTERNS OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
5. MP71-15 CANCER CONTROL RATES IN ADEQUATE VERSUS INADEQUATE TREATMENT WITH ADJUVANT IMMUNOTHERAPY INSTILLATIONS WITH BCG
6. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)
7. MP14-11 THE ADDED VALUE OF CONCOMITANT WHOLE-PELVIS SALVAGE RADIATION THERAPY IN OLIGO-RECURRENT PROSTATE CANCER PATIENTS TREATED WITH METASTASIS-DIRECTED THERAPY FOR DISTANT POSITIVE UPTAKES AT PSMA PET
8. MP16-11 LONG-TERM OUTCOMES OF PTA HIGH GRADE INTERMEDIATE AND HIGH RISK BLADDER CANCER PATIENTS
9. MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL
10. MP53-02 RISK OF NODE METASTASES IN MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMO- OR IMMUNOTHERAPY AND RADICAL CYSTECTOMY WITH BILATERAL PELVIC LYMPH NODE DISSECTION
11. PD38-03 DETECTION OF LYMPH NODE INVOLVEMENT BEFORE RADICAL CYSTECTOMY: DIAGNOSTIC PERFORMANCE OF 18F-FDG PET/CT AND IMPLICATIONS IN THE THERAPEUTIC MANAGEMENT
12. PD30-01 DEFINING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: A COMPARATIVE STUDY OF EAU AND IBCG CRITERIA
13. PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211
14. MP58-12 VENOUS TUMOUR THROMBUS IN RENAL CELL CARCINOMA: LOCALLY ADVANCED OR METASTATIC DISEASE?
15. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?
16. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
17. MP58-19 DETECTION OF PULMONARY LESION DURING FOLLOW-UP AFTER SURGERY FOR LOCALIZED RENAL CELL CARCINOMA: DISEASE PROGRESSION OR A PRIMARY LUNG CANCER?
18. PD24-03 BEST TREATMENT FOR OLIGOMETASTATIC RENAL CANCER: A QUASI-INDIVIDUAL PATIENT DATA ANALYSIS
19. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
20. MP28-16 GENERALIZABILITY OF THE MK-6482-004 TRIAL TO REAL-WORLD VHL PATIENTS: RESULTS FROM A PROSPECTIVE SURVEILLANCE STUDY
21. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
22. MP11-08 EXPLORING THE EFFECT OF METASTASIS DIRECTED THERAPY ON PROGRESSION PATTERNS OF PATIENTS WITH POSITIVE 68Ga-PSMA PET/CT AND BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
23. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
24. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT
25. PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211
26. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?
27. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
28. MP58-19 DETECTION OF PULMONARY LESION DURING FOLLOW-UP AFTER SURGERY FOR LOCALIZED RENAL CELL CARCINOMA: DISEASE PROGRESSION OR A PRIMARY LUNG CANCER?
29. MP58-12 VENOUS TUMOUR THROMBUS IN RENAL CELL CARCINOMA: LOCALLY ADVANCED OR METASTATIC DISEASE?
30. MP11-08 EXPLORING THE EFFECT OF METASTASIS DIRECTED THERAPY ON PROGRESSION PATTERNS OF PATIENTS WITH POSITIVE 68Ga-PSMA PET/CT AND BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
31. MP11-06 THE PROGNOSTIC ROLE OF 68Ga-PSMA PET/CT AND THE IMPACT OF METASTASIS-DIRECTED THERAPY ON CANCER PROGRESSION IN MEN WITH BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER. RESULTS FROM A LARGE, SINGLE INSTITUTION SERIES
32. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
33. Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy
34. MP40-19 HOW TO IDENTIFY PATIENTS SUITABLE FOR CONSERVATIVE MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC) ACCORDING TO TUMOR SIZE: IMPLICATIONS FOR CLINICAL GUIDELINES
35. MP12-07 THE ANATOMICAL LOCATION OF LYMPHADENOPATHIES AT IMAGING PREDICTS THE RISK OF LYMPH NODE INVASION AT FINAL PATHOLOGY IN PATIENTS WITH RENAL CELL CARCINOMA
36. PD59-07 NEGLECTED LYMPH NODAL METASTASES IN PATIENTS WITH RENAL CANCER: WHEN TO EXTEND THE ANATOMICAL TEMPLATE OF LYMPH NODE DISSECTION DURING NEPHRECTOMY
37. MP51-14 IMPACT OF 68GA-PSMA PET/CT AND METASTASIS-DIRECTED THERAPY ON CLINICAL RECURRENCE IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS FROM A SINGLE CENTER SERIES
38. MP56-02 NEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01
39. MP56-04 THE ROLE OF FDG PET IN THE STAGING OF BLADDER CANCER PATIENTS CANDIDATE FOR RADICAL CYSTECTOMY
40. MP48-14 WHEN NODE-POSITIVE PROSTATE CANCER SHOULD BE CONSIDERED A SYSTEMIC DISEASE? ASSESSING THE PROGNOSTIC ROLE OF PREOPERATIVE 68GA-PSMA PET/CT RESULTS IN PATIENTS WITH LYMPH NODE INVASION AT FINAL PATHOLOGY
41. MP50-09 IMAGING INTENSITY AFTER SURGERY FOR CLEAR CELL RENAL CELL CARCINOMA
42. MP48-13 THE KEY ROLE OF CONCOMITANT ANDROGEN-DEPRIVATION THERAPY ON THE EFFICACY OF IMAGING GUIDED TREATMENTS IN MEN WITH BIOCHEMICAL RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND POSITIVE 68GA-PSMA PET/CT SCAN
43. PD35-02 WHEN IS NEOADJUVANT ANDROGEN DEPRIVATION THERAPY BENEFICIAL FOR HIGHLY AGGRESSIVE PROSTATE CANCER CANDIDATES TO RADICAL PROSTATECTOMY? IMPLICATIONS FOR MULTI-MODAL TAILORED APPROACHES AND TRIALS DESIGN
44. PD60-03 THE IMPACT OF HISTOLOGICAL VARIANTS ON THE PERFORMANCE CHARACTERISTICS OF 68GA-PSMA PET/CT IN THE PRIMARY AND RECURRENT SETTING
45. MP48-12 OPTIMIZING TIMING AND INDICATIONS FOR 68GA-PSMA PET/CT IN PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
46. MP50-03 SYSTEMATIC DEFINITION OF TREATMENT MODALITY AND CLINICAL OUTCOMES REPORTING SYSTEM IN CASE OF SURGICAL TREATMENT FOR VON HIPPEL-LINDAU RENAL CELL CARCINOMA
47. PD15-08 WHEN TO DE-INTENSIFY ONCOLOGIC SURVEILLANCE SCHEME FOR NON-CLEAR CELL RENAL CELL CARCINOMA
48. MP47-18 SUSTAINABLE MULTIDISCIPLINARY TEAM REFERRAL FOR NON-METASTATIC RENAL CELL CARCINOMA: A SURVIVAL-BASED RECOMMENDATION
49. PD60-02 CAN PELVIC LYMPH NODE DISSECTION BE OMITTED AT THE TIME OF RADICAL PROSTATECTOMY IN PATIENTS WITH A NEGATIVE PREOPERATIVE 68GA-PSMA PET/CT? THE IMPORTANCE OF PATIENT RISK STRATIFICATION ACCORDING TO INDIVIDUAL RISK OF LYMPH NODE METASTASES
50. MP12-06 ONCOLOGIC OUTCOMES IN PATIENTS DIAGNOSED WITH pT3aN0M0 RENAL CELL CANCER ACCORDING TO RENAL VEIN THROMBUS OR FAT INVASION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.